Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 2,611 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Application Use Clear all

Conditions: Atrial Fibrillation, Arterial Hypertension
Interventions: Redo PVI, PVI + RDN; Procedure
Lead sponsor: Meshalkin Research Institute of Pathology of Circulation; Network
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mild Cognitive Impairment, Neuropsychiatric Syndrome
Interventions: tDCS; Device
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Autistic Disorder, Autism, ASD
Interventions: MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time; Other
Lead sponsor: ImagiRation, LLC; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 6,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Arteriosclerosis
Interventions: Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo; Drug
Lead sponsor: Kronos Longevity Research Institute; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 728 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more

Conditions: HIV Prevention
Interventions: Once Daily Application of TFV RG 1% Gel - Vaginal, Once Daily Application of TFV RG 1% gel - Rectal; Drug
Lead sponsor: CONRAD; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Otitis Media, Ear Infection, Pediatric Infectious Disease
Interventions: Changes to the electronic health record (EHR), Individualized audit and feedback reporting for clinicians, Clinician education sessions, Use of a shared decision-making (SDM) aide, Shared decision-making (SDM) education; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 6 Months to 17 Years
Enrollment: 1,566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Murray, Utah

Conditions: Scar
Interventions: Topical Tocotrienol (TCT), Oral Tocotrienol Capsules (TCT), Tamoxifen Cream, Placebo cream, placebo capsule; Device · Dietary Supplement
Lead sponsor: Chandan K Sen; Other
Eligibility: 18 Years to 50 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Carfilzomib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Boca Raton, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Class I Obesity, Pediatric Obesity
Interventions: Virtual Housecalls; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 12 Years to 15 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Henrico, Virginia

Conditions: Cigarette Smoking Behavior
Interventions: Control, Product Category Score, Product Category Rank, Product Tiers; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Heart Failure, Quality of Life
Interventions: web based telemonitoring system, Conventional; Other
Lead sponsor: Danbury Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Danbury, Connecticut

Conditions: Skin Infection
Interventions: Medicinal honey, Bacitracin; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Tobacco Use Cessation
Interventions: iCanQuit, iCanQuit+Motiv8, Florida quit line; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: HIV Infection, Tobacco-Related Carcinoma
Interventions: Computed Tomography, Smoking Cessation Intervention; Procedure · Behavioral
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 45 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more

Conditions: Substance Use Disorders, HIV
Interventions: Seva; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Missoula, Montana • The Bronx, New York • Madison, Wisconsin

Conditions: Breast Cancer, Insomnia, Weight Gain
Interventions: Cognitive-Behavioral Therapy for Insomnia (CBT-I), Sleep Education Control (EDU); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Lutherville, Maryland

Conditions: Anxiety, Depression, Trauma, Behavior Problem
Interventions: FIRST, Usual Care; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Cambridge, Massachusetts • Austin, Texas

Conditions: Military Family, Brain Injuries, Traumatic
Interventions: Problem-Solving Thearpy; Behavioral
Lead sponsor: Duquesne University; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gait, Unsteady
Interventions: Patients using Step Test Application and Accelerometer; Other
Lead sponsor: University of Chicago; Other
Eligibility: 60 Years and older
Enrollment: 100 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: MGD-Meibomian Gland Dysfunction
Interventions: Thermal Vectored Pulsation; Device
Lead sponsor: Dunes Eye Consultants; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dakota Dunes, South Dakota

Conditions: Depression, Cancer, Adolescent, Young Adult, Adult
Interventions: AYA Survivors Coping and Emotional Needs Toolkit (ASCENT); Behavioral
Lead sponsor: East Carolina University; Other
Eligibility: 15 Years to 39 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Urinary Incontinence
Interventions: Implementation Strategy: Foundational Arm, Implementation Strategy: REACH Arm; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dental Plaque, Gingivitis
Interventions: Mouthwash, Floss, Toothbrush, Toothpaste; Drug · Device
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: HIV-related Mild Neurocognitive Disorder
Interventions: Transcranial Direct Current Stimulation (tDCS), Computer-based Cognitive Training, Watching Educational Videos; Procedure · Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 50 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Search by objective public record fields.

Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI

CogT BEEM Study (a tDCS Study)

Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD

Kronos Early Estrogen Prevention Study (KEEPS)

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections

Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Virtual Housecalls: Redesigning Pediatric Primary Care Adolescent Obesity Treatment

Effects of Tobacco Abuse Liability-dependent Taxes in the ETM

Use of Telemonitoring System in Heart Failure Patients

The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown

Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care

Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

Testing FIRST in Youth Outpatient Psychotherapy

Effects of PSTon Mental Health Outcomes in Caregivers of Post-9/11 Combat Veterans With a Traumatic Brain Injury

At-home Walking Cadence Functional Assessment and Recovery Trajectory for Older Adults Undergoing Major Surgery

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

Evaluating Procedures for a Study of the AYA Survivors Coping and Emotional Needs Toolkit

Implementing a Mobile Health Application for Women Veterans With Urinary Incontinence (MyHealtheBladder): Function QUERI 3.0

Comparative Efficacy of Floss and Essential Oil/CPC+Zn Mouthwashes in Reducing Dental Plaque and Gingivitis

Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV